Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Drug Metabolism, Poor, CYP2C19-Related
  • Drug Metabolism, Poor, CYP2D6-Related
  • Drug-Related Side Effects and Adverse Reactions
  • Side Effect of Drug

NCT number NCT06322238
Study type Interventional
Source Mayo Clinic
Contact
Status Not yet recruiting
Phase Phase 2
Start date June 2024
Completion date April 2026

See also
  Status Clinical Trial Phase
Completed NCT04696445 - Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery
Recruiting NCT01477242 - The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department N/A
Recruiting NCT05775419 - Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC N/A
Completed NCT06035900 - Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate Phase 1
Completed NCT04475029 - Methadone in Cystectomy Patients N/A
Recruiting NCT03996941 - Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)
Recruiting NCT04701151 - NORTH-REG Dwell-Time Study Phase 4
Not yet recruiting NCT04644354 - The Efficacy of Nifedipine in the Management of Preterm Labor
Completed NCT03183908 - FLUAD® vs. Fluzone® High-Dose Study Phase 4